Sponsors (10)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Directs federal health agencies to expand research on endometrial cancer and to run a public education effort focused on incidence, risk factors, and disparities. The NIH is required to strengthen, coordinate, and communicate research on endometrial cancer — including ensuring African-American women are represented in clinical trials in proportion to incidence — and is authorized $1,000,000 per year for FY2026–FY2028. The CDC is directed to develop and share public informational materials about endometrial cancer (including materials targeted to African-American women) in consultation with HRSA, with funding authorized as needed for FY2026–FY2028.
The bill aims to improve awareness, research, and equity around rising endometrial cancer risks—especially for African-American and other minority women—by funding CDC outreach and modest NIH research efforts, while creating modest but potentially open-ended federal costs and posing practical challenges for trial implementation and impact scale-up.
Women — especially African-American and Asian women — will get better-targeted information and outreach about rising endometrial cancer risks and disparities, which should improve awareness, early detection, and access to care.
Patients with endometrial cancer and health systems — NIH-authorized research coordination and funding aim to expand studies on causes, prevention, and treatment, likely accelerating discoveries and improved care.
African-American women and other underrepresented groups — greater emphasis on enrolling diverse participants in NIH-supported clinical trials will improve the relevance and equity of research findings and treatments for those groups.
Taxpayers — the bill authorizes new federal activities (including an open-ended CDC funding clause) that could produce ongoing or unpredictable federal costs.
Patients and health systems — the $1,000,000 annual NIH authorization is modest and may be insufficient to scale meaningful research programs or large clinical trial recruitment, limiting the bill's practical impact.
Patients and racial-ethnic-minority participants — mandating or emphasizing proportional representation in trials could complicate recruitment or slow enrollment if incidence-based targets are hard to meet quickly, delaying research and access to experimental therapies.
Introduced September 9, 2025 by David Scott · Last progress September 9, 2025